160 related articles for article (PubMed ID: 22596233)
1. Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence.
Truong M; Yang B; Wagner J; Kobayashi Y; Rajamanickam V; Brooks J; Jarrard DF
Br J Cancer; 2012 Jun; 107(1):100-7. PubMed ID: 22596233
[TBL] [Abstract][Full Text] [Related]
2. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.
Walton TJ; Li G; Seth R; McArdle SE; Bishop MC; Rees RC
Prostate; 2008 Feb; 68(2):210-22. PubMed ID: 18092350
[TBL] [Abstract][Full Text] [Related]
3. Methylation of Integrin α4 and E-Cadherin Genes in Human Prostate Cancer.
Mostafavi-Pour Z; Kianpour S; Dehghani M; Mokarram P; Torabinejad S; Monabati A
Pathol Oncol Res; 2015 Sep; 21(4):921-7. PubMed ID: 25743258
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic regulation of the KAI1 metastasis suppressor gene in human prostate cancer cell lines.
Sekita N; Suzuki H; Ichikawa T; Kito H; Akakura K; Igarashi T; Nakayama T; Watanabe M; Shiraishi T; Toyota M; Yoshie O; Ito H
Jpn J Cancer Res; 2001 Sep; 92(9):947-51. PubMed ID: 11572762
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide differentially methylated genes in prostate cancer tissues from African-American and Caucasian men.
Devaney JM; Wang S; Furbert-Harris P; Apprey V; Ittmann M; Wang BD; Olender J; Lee NH; Kwabi-Addo B
Epigenetics; 2015; 10(4):319-28. PubMed ID: 25864488
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays.
Kron K; Pethe V; Briollais L; Sadikovic B; Ozcelik H; Sunderji A; Venkateswaran V; Pinthus J; Fleshner N; van der Kwast T; Bapat B
PLoS One; 2009; 4(3):e4830. PubMed ID: 19283074
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer.
Luo W; Karpf AR; Deeb KK; Muindi JR; Morrison CD; Johnson CS; Trump DL
Cancer Res; 2010 Jul; 70(14):5953-62. PubMed ID: 20587525
[TBL] [Abstract][Full Text] [Related]
8. Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells.
Liu Z; Marquez M; Nilsson S; Holmberg AR
Oncol Rep; 2008 Jul; 20(1):151-4. PubMed ID: 18575731
[TBL] [Abstract][Full Text] [Related]
9. SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation.
Acun T; Oztas E; Yagci T; Yakicier MC
BMC Cancer; 2011 Jun; 11():223. PubMed ID: 21645397
[TBL] [Abstract][Full Text] [Related]
10. Analysis of promoter non-CG methylation in prostate cancer.
Truong M; Yang B; Wagner J; Desotelle J; Jarrard DF
Epigenomics; 2013 Feb; 5(1):65-71. PubMed ID: 23414321
[TBL] [Abstract][Full Text] [Related]
11. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
Phillip CJ; Giardina CK; Bilir B; Cutler DJ; Lai YH; Kucuk O; Moreno CS
BMC Cancer; 2012 Apr; 12():145. PubMed ID: 22494660
[TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation of the vascular endothelial growth factor receptor-1 gene in prostate cancer.
Yamada Y; Watanabe M; Yamanaka M; Hirokawa Y; Suzuki H; Takagi A; Matsuzaki T; Sugimura Y; Yatani R; Shiraishi T
Cancer Sci; 2003 Jun; 94(6):536-9. PubMed ID: 12824880
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
[TBL] [Abstract][Full Text] [Related]
14. Methylation mediated silencing of TMS1/ASC gene in prostate cancer.
Das PM; Ramachandran K; Vanwert J; Ferdinand L; Gopisetty G; Reis IM; Singal R
Mol Cancer; 2006 Jul; 5():28. PubMed ID: 16848908
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
[TBL] [Abstract][Full Text] [Related]
17. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
[TBL] [Abstract][Full Text] [Related]
18. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
Vinarskaja A; Schulz WA; Ingenwerth M; Hader C; Arsov C
Urol Oncol; 2013 Jul; 31(5):622-7. PubMed ID: 21803613
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of the SPARC promoter and its prognostic value for prostate cancer.
Liu T; Qiu X; Zhao X; Yang R; Lian H; Qu F; Li X; Guo H
Oncol Rep; 2018 Feb; 39(2):659-666. PubMed ID: 29207175
[TBL] [Abstract][Full Text] [Related]
20. Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence.
Stott-Miller M; Zhao S; Wright JL; Kolb S; Bibikova M; Klotzle B; Ostrander EA; Fan JB; Feng Z; Stanford JL
Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1331-9. PubMed ID: 24718283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
